MX386919B - Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. - Google Patents

Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.

Info

Publication number
MX386919B
MX386919B MX2017003370A MX2017003370A MX386919B MX 386919 B MX386919 B MX 386919B MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 386919 B MX386919 B MX 386919B
Authority
MX
Mexico
Prior art keywords
gep
nen
methods
compositions
kits
Prior art date
Application number
MX2017003370A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003370A (es
Inventor
Ignat Drozdov
Irvin Mark Modlin
Mark Kidd
Original Assignee
Clifton Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clifton Life Sciences LLC filed Critical Clifton Life Sciences LLC
Publication of MX2017003370A publication Critical patent/MX2017003370A/es
Publication of MX386919B publication Critical patent/MX386919B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2017003370A 2014-09-15 2015-09-15 Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. MX386919B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050465P 2014-09-15 2014-09-15
PCT/US2015/050274 WO2016044330A1 (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Publications (2)

Publication Number Publication Date
MX2017003370A MX2017003370A (es) 2017-11-22
MX386919B true MX386919B (es) 2025-03-19

Family

ID=54207775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003370A MX386919B (es) 2014-09-15 2015-09-15 Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
MX2021012347A MX2021012347A (es) 2014-09-15 2017-03-14 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012347A MX2021012347A (es) 2014-09-15 2017-03-14 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.

Country Status (13)

Country Link
US (4) US10407730B2 (cg-RX-API-DMAC7.html)
EP (2) EP3194618B1 (cg-RX-API-DMAC7.html)
JP (2) JP6782700B2 (cg-RX-API-DMAC7.html)
KR (2) KR102762958B1 (cg-RX-API-DMAC7.html)
CN (1) CN107208132A (cg-RX-API-DMAC7.html)
AU (3) AU2015317893B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959670C (cg-RX-API-DMAC7.html)
DK (2) DK3929303T3 (cg-RX-API-DMAC7.html)
ES (2) ES3013599T3 (cg-RX-API-DMAC7.html)
IL (2) IL250867B (cg-RX-API-DMAC7.html)
MX (2) MX386919B (cg-RX-API-DMAC7.html)
PL (2) PL3194618T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016044330A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407730B2 (en) 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
MX2019014026A (es) * 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.
CN118910259A (zh) * 2017-11-30 2024-11-08 液体活检研究有限责任公司 使用基因表达测定预测肽受体放射治疗
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
US11948296B2 (en) * 2018-07-30 2024-04-02 Agency For Science, Technology And Research Method and system for assessing fibrosis in a tissue sample
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
FR3110764B1 (fr) 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images
CN113215255B (zh) * 2021-04-26 2022-04-05 山东天川精准医疗科技有限公司 用于肝癌早期诊断或预后的生物标记物及其用途
CN120153081A (zh) * 2022-07-15 2025-06-13 埃门多生物公司 Aplp2安全港位点敲入策略
CN120380169A (zh) * 2022-09-30 2025-07-25 液体活检研究有限责任公司 用于在唾液中检测神经内分泌癌的方法
CN117292755B (zh) * 2023-08-09 2026-02-06 郑州大学 多模态临界边生物标志物识别方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084883A1 (en) 2003-08-25 2005-04-21 The Johns Hopkins University School Of Medicine Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis
JP5728380B2 (ja) * 2008-06-12 2015-06-03 シンタクシン リミテッドSyntaxin Limited 神経内分泌疾患の抑制
AU2012223288B2 (en) 2011-03-01 2017-03-30 Yale University Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
US10407730B2 (en) 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Also Published As

Publication number Publication date
AU2015317893A1 (en) 2017-03-23
US20260043085A1 (en) 2026-02-12
JP7157788B2 (ja) 2022-10-20
KR20170045365A (ko) 2017-04-26
IL281355B (en) 2022-02-01
JP2021019618A (ja) 2021-02-18
IL281355A (en) 2021-04-29
KR20250021631A (ko) 2025-02-13
US20220325351A1 (en) 2022-10-13
AU2021212151A1 (en) 2021-08-26
PL3194618T3 (pl) 2021-12-13
BR112017005279A2 (pt) 2017-12-12
CA2959670A1 (en) 2016-03-24
DK3929303T3 (da) 2025-03-03
AU2023258444A1 (en) 2023-11-23
MX2017003370A (es) 2017-11-22
US10407730B2 (en) 2019-09-10
EP3194618A1 (en) 2017-07-26
US11168372B2 (en) 2021-11-09
US20190345568A1 (en) 2019-11-14
AU2015317893B2 (en) 2021-05-20
AU2021212151B2 (en) 2023-08-03
EP3929303A1 (en) 2021-12-29
CA2959670C (en) 2024-02-20
JP6782700B2 (ja) 2020-11-11
CN107208132A (zh) 2017-09-26
PL3929303T3 (pl) 2025-04-28
US12258633B2 (en) 2025-03-25
EP3194618B1 (en) 2021-04-21
MX2021012347A (es) 2021-10-22
IL250867A0 (en) 2017-04-30
JP2017528164A (ja) 2017-09-28
DK3194618T3 (da) 2021-07-12
WO2016044330A1 (en) 2016-03-24
EP3929303B1 (en) 2024-12-04
ES3013599T3 (en) 2025-04-14
KR102762958B1 (ko) 2025-02-04
IL250867B (en) 2021-03-25
ES2881474T3 (es) 2021-11-29
US20160076106A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
MX2017006242A (es) Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas.
MX2016011377A (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX2015012303A (es) Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos.
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MX380642B (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
MX2019006866A (es) Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
HK1232290A1 (zh) 检测人类骨膜蛋白的新型测定
WO2016112174A3 (en) Biomarkers of Sleep Deprivation and Cognitive Impairment
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
EP4328324A3 (en) Methods of diagnosing epilepsy
WO2017156154A9 (en) Compositions for characterizing development of esophageal adenocarcinoma in patients and methods of use thereof